Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,206 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control I Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

NCT04041648
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System, Placebo Solution
Drug · Device · Other
Lead sponsor
Pharmosa Biopharm Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer

NCT00060320
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
black cohosh, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
13
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

NCT01756950
View directory record Official record
Conditions
Influenza
Interventions
2 mg/kg CR8020, 5 mg/kg CR8020, 15 mg/kg CR8020, 30 mg/kg CR8020, 50 mg/kg CR8020, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

NCT04055168
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD6615, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Magnesium Supplementation in People With XMEN Syndrome

NCT02496676
View directory record Official record
Conditions
XMEN
Interventions
Magnesium L-threonate, Placebo, Intravenous (IV) magnesium sulfate (MgSO4)
Dietary Supplement · Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional

Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

NCT01827618
View directory record Official record
Conditions
Invasive Bladder Cancer Stage II
Interventions
Rapamycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Phase 1 Interventional

Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

NCT07237659
View directory record Official record
Conditions
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Interventions
NTR1011
Drug
Lead sponsor
Neutrolis
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Apple Valley, California • Beverly Hills, California • Covina, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional

The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients

NCT06604247
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Cognitive Behavioral therapy for insomnia (CBT-I)
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

WOOP VA: Promoting Weight Management in Primary Care

NCT05014984
View directory record Official record
Conditions
Obesity
Interventions
mental contrasting with implementation intentions, telephone-delivered, telehealth-delivered, and or in-person MOVE! or TeleMOVE!, Information About Diet, Physical Activity, and Weight Management (Baseline Visit - 10 minutes): All, Telephone MCII Check-ins (30 minutes at 3 days, 4 weeks, and 2 months after baseline visit)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities

NCT02513407
View directory record Official record
Conditions
Healthy Subject
Interventions
Behavioral Dietary Intervention, Educational Intervention, Exercise Intervention, Laboratory Biomarker Analysis, Questionnaire Administration
Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intervention to Improve Parent Communication About Sexuality

NCT07672067
View directory record Official record
Conditions
HIV/STI Incidence, Communication About Health Information
Interventions
Parents ASSIST
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
12 Years to 100 Years
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

NCT01340599
View directory record Official record
Conditions
Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry
Dietary Supplement · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
45 Years to 75 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

NCT00606112
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2009 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Effects of Palliative Care on Quality of Life and Symptom Control in Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer That Can Be Removed by Surgery

NCT00823667
View directory record Official record
Conditions
Lung Cancer
Interventions
educational intervention, medical chart review, questionnaire administration, end-of-life treatment/management, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Oct 25, 2026, 4:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Role of Sweetness in Glucose Regulation

NCT03844230
View directory record Official record
Conditions
Obesity
Interventions
Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition, Control- Stimulation, Experimental I- Stimulation, Experimental II- Stimulation, Sensory Evaluation
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

NCT02311907
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Interventions
Carboplatin, Glutathione, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
390
States / cities
Mobile, Alabama • Fairbanks, Alaska • Scottsdale, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

NCT04849377
View directory record Official record
Conditions
Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
RT 50 Gy, RT 54 GY, RT 60 GY, Induction Therapy, Carboplatin, Cisplatin 200, Cisplatin 240
Radiation · Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

NCT02931565
View directory record Official record
Conditions
Achalasia
Interventions
Olinciguat, Matching Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Bristol, Connecticut • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer

NCT00043069
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
calcium carbonate, cholecalciferol, Estrogen Antagonists, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
112
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Results available

Health Behavior Change for Hospitalized Veterans

NCT01602172
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Brief Alcohol Intervention, Lifestyle brochures
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 25, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

NCT00752167
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Asthma
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602
View directory record Official record
Conditions
Healthy Male and Female Japanese Volunteers
Interventions
NXL104, CAZ104, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

NCT02207231
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab 100 mg, Placebo for guselkumab, Adalimumab, Placebo for adalimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
26
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 25, 2026, 4:15 AM EDT